Literature DB >> 28335616

Predictors of CD4 health and viral suppression outcomes for formerly homeless people living with HIV/AIDS in scattered site supportive housing.

Elizabeth A Bowen1, James Canfield2, Suzanne Moore3, Midge Hines3, Brent Hartke3, Chrissy Rademacher3.   

Abstract

Stable housing is key to improving health outcomes for people living with HIV/AIDS. Though many formerly homeless HIV positive individuals reside in supportive housing, little research has examined biometric HIV health outcomes for residents of these programs. Through a community-based research partnership, this study analyzed secondary data from a Shelter Plus Care supportive housing program in Cincinnati, Ohio to examine the likelihood of participants achieving a healthy CD4 count (>500 cells/mm3) and viral suppression (viral load <200 copies/mL) while in supportive housing and to identify participant characteristics associated with these outcomes. The study sample was 86 participants who entered the program between 2008 and 2016, including 50 current residents and 36 exited participants. Participants' average length of stay in Shelter Plus Care was 35.2 months (range 3.2-108.1 months) during the study period. Bivariate analysis indicated statistically significant improvements on both outcome variables, with 45% of participants achieving a healthy CD4 count and 79% achieving viral suppression by program exit or most recent time point. Participants who had health insurance at intake and who had never been incarcerated were more likely to achieve viral suppression, and longer length of stay in the program was also positively associated with viral suppression. These results add to the literature on the relationship between housing conditions and HIV health outcomes by demonstrating that residence in supportive housing is associated with improvements in CD4 count and viral load for a sample of formerly homeless persons living with HIV/AIDS, two-thirds of whom had co-occurring physical health, mental health, or substance abuse problems. Further research collaborations should expand on these findings to examine the service packages that are associated with optimal HIV health outcomes for supportive housing residents.

Entities:  

Keywords:  Homeless; shelter plus care; social determinants of health; supportive housing; viral suppression

Mesh:

Substances:

Year:  2017        PMID: 28335616     DOI: 10.1080/09540121.2017.1307920

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  11 in total

1.  Viral suppression among HIV-infected methadone-maintained patients: The role of ongoing injection drug use and adherence to antiretroviral therapy (ART).

Authors:  Roman Shrestha; Michael M Copenhaver
Journal:  Addict Behav       Date:  2018-05-31       Impact factor: 3.913

2.  Health-related quality of life and related factors among chronically homeless adults living in different permanent supportive housing models: a cross-sectional study.

Authors:  Antoinette L Spector; Katherine G Quinn; Timothy L McAuliffe; Wayne DiFranceisco; Arturo Bendixen; Julia Dickson-Gomez
Journal:  Qual Life Res       Date:  2020-03-28       Impact factor: 4.147

3.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

Authors:  Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding
Journal:  JAMA       Date:  2018-07-24       Impact factor: 56.272

4.  HIV-Related Stigma, Motivation to Adhere to Antiretroviral Therapy, and Medication Adherence Among HIV-Positive Methadone-Maintained Patients.

Authors:  Roman Shrestha; Frederick L Altice; Michael M Copenhaver
Journal:  J Acquir Immune Defic Syndr       Date:  2019-02-01       Impact factor: 3.731

5.  Understanding the impact of a residential housing programme for people living with HIV/AIDS: a realist evaluation protocol.

Authors:  Shaneice Fletcher-Hildebrand; Hubert Alimezelli; Tracey Carr; Karen Lawson; Anum Ali; Gary Groot
Journal:  BMJ Open       Date:  2021-04-05       Impact factor: 2.692

6.  The effect of homelessness on viral suppression in an underserved metropolitan area of middle Tennessee: potential implications for ending the HIV epidemic.

Authors:  Vladimir Berthaud; Livette Johnson; Ronda Jennings; Maxine Chandler-Auguste; Abosede Osijo; Marie T Baldwin; Patricia Matthews-Juarez; Paul Juarez; Derek Wilus; Mohammad Tabatabai
Journal:  BMC Infect Dis       Date:  2022-02-10       Impact factor: 3.090

7.  Examining Barriers to Medication Adherence and Retention in Care among Women Living with HIV in the Face of Homelessness and Unstable Housing.

Authors:  Sofia B Fernandez; Cindy Lopez; Cynthia Ibarra; Diana M Sheehan; Robert A Ladner; Mary Jo Trepka
Journal:  Int J Environ Res Public Health       Date:  2022-09-13       Impact factor: 4.614

8.  Housing Subsidies and Housing Stability are Associated with Better HIV Medical Outcomes Among Persons Who Experienced Homelessness and Live with HIV and Mental Illness or Substance Use Disorder.

Authors:  Ellen W Wiewel; Tejinder P Singh; Yaoyu Zhong; Christopher M Beattie; Sungwoo Lim; Sarah Walters; Sarah L Braunstein; John Rojas
Journal:  AIDS Behav       Date:  2020-11

9.  Viral Rebound Among Persons With Diagnosed HIV Who Achieved Viral Suppression, United States.

Authors:  Jason A Craw; Linda Beer; Yunfeng Tie; Tom Jaenicke; R Luke Shouse; Joseph Prejean
Journal:  J Acquir Immune Defic Syndr       Date:  2020-06-01       Impact factor: 3.771

10.  Addressing disparities in the health of persons with HIV attributable to unstable housing in the United States: The role of the Ryan White HIV/AIDS Program.

Authors:  Amy Griffin; Antigone Dempsey; Wendy Cousino; Latham Avery; Harold Phillips; Emeka Egwim; Laura Cheever
Journal:  PLoS Med       Date:  2020-03-02       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.